开云app官网登录入口网页版-官方正版

#转移性非鳞状非小细胞肺癌#

8篇内容 | 763人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1600773, encodeId=05491600e7381, content=<a href='/topic/show?id=86189344280' target=_blank style='color:#2F92EE;'>#转移性非鳞状非小细胞肺癌#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=221052, objectId=063622105235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063622105235, replyNumber=0, likeNumber=62, createdTime=2021-11-27, rootId=0, userName=xfpan18, userId=f9bb18811579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063622105235, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=063622105235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600772, encodeId=a9f61600e72b4, content=<a href='/topic/show?id=86189344280' target=_blank style='color:#2F92EE;'>#转移性非鳞状非小细胞肺癌#</a>, objectTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, objectType=article, longId=215469, objectId=aafc2154691d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafc2154691d, replyNumber=0, likeNumber=46, createdTime=2021-08-10, rootId=0, userName=xfpan18, userId=f9bb18811579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafc2154691d, moduleTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aafc2154691d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600771, encodeId=9dd71600e713b, content=<a href='/topic/show?id=86189344280' target=_blank style='color:#2F92EE;'>#转移性非鳞状非小细胞肺癌#</a>, objectTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, objectType=article, longId=214763, objectId=e0a7214e632f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a7214e632f, replyNumber=0, likeNumber=39, createdTime=2021-07-26, rootId=0, userName=xfpan18, userId=f9bb18811579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a7214e632f, moduleTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e0a7214e632f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600770, encodeId=b3d71600e70c9, content=<a href='/topic/show?id=86189344280' target=_blank style='color:#2F92EE;'>#转移性非鳞状非小细胞肺癌#</a>, objectTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, objectType=article, longId=213120, objectId=686b21312019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686b21312019, replyNumber=0, likeNumber=58, createdTime=2021-06-25, rootId=0, userName=xfpan18, userId=f9bb18811579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686b21312019, moduleTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=686b21312019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600769, encodeId=7fd11600e69b3, content=<a href='/topic/show?id=86189344280' target=_blank style='color:#2F92EE;'>#转移性非鳞状非小细胞肺癌#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=39, createdTime=2021-06-17, rootId=0, userName=xfpan18, userId=f9bb18811579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600768, encodeId=370b1600e6821, content=<a href='/topic/show?id=86189344280' target=_blank style='color:#2F92EE;'>#转移性非鳞状非小细胞肺癌#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=189823, objectId=597d18982326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597d18982326, replyNumber=0, likeNumber=58, createdTime=2020-03-13, rootId=0, userName=xfpan18, userId=f9bb18811579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597d18982326, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=597d18982326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600767, encodeId=e9b71600e67a5, content=<a href='/topic/show?id=86189344280' target=_blank style='color:#2F92EE;'>#转移性非鳞状非小细胞肺癌#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=184290, objectId=431b184290f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b184290f9, replyNumber=0, likeNumber=63, createdTime=2019-12-08, rootId=0, userName=xfpan18, userId=f9bb18811579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b184290f9, moduleTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=431b184290f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1600766, encodeId=d36f1600e66ee, content=<a href='/topic/show?id=86189344280' target=_blank style='color:#2F92EE;'>#转移性非鳞状非小细胞肺癌#</a>, objectTitle=NEJM：Atezolizumab一线治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=140057, objectId=430314005e99, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430314005e99, replyNumber=0, likeNumber=50, createdTime=2018-06-07, rootId=0, userName=xfpan18, userId=f9bb18811579, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430314005e99, moduleTitle=NEJM：Atezolizumab一线治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=430314005e99)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

转移性非鳞状非小细胞肺癌

2020-05-29

xfpan18 (审核中...)

前往app查看评论内容

#转移性非鳞状非小细胞肺癌#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2021-11-27

xfpan18 (审核中...)

前往app查看评论内容

#转移性非鳞状非小细胞肺癌#

JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。

2021-08-10

xfpan18 (审核中...)

前往app查看评论内容

#转移性非鳞状非小细胞肺癌#

J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150

2021-07-26

xfpan18 (审核中...)

前往app查看评论内容

#转移性非鳞状非小细胞肺癌#

J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究

2021-06-25

xfpan18 (审核中...)

前往app查看评论内容

#转移性非鳞状非小细胞肺癌#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2021-06-17

xfpan18 (审核中...)

前往app查看评论内容

#转移性非鳞状非小细胞肺癌#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2020-03-13

xfpan18 (审核中...)

前往app查看评论内容

#转移性非鳞状非小细胞肺癌#

罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌

2019-12-08

xfpan18 (审核中...)

前往app查看评论内容

#转移性非鳞状非小细胞肺癌#

NEJM：Atezolizumab一线治疗转移性非鳞状非小细胞肺癌

2018-06-07

科室
- - 订阅+
  - 更多科室
工具
服务